References
- Sekijima Y, Yoshida K, Tokuda T, Ikeda S. Familial Transthyretin Amyloidosis. In: Pagon RA, Adam MP, Bird TD, Dolan CR, Fong CT, Stephens K, eds. Seattle (WA): GeneReviews; 2012
- Zeldenrust SR. Genotype–phenotype correlation in FAP. Amyloid 2012;19:22–4
- Mitsuhashi S, Yazaki M, Tokuda T, Yamamoto K, Ikeda S. MRI analysis on a patient with the V30M mutation is characteristic of leptomeningeal amyloid. Amyloid 2004;11:265–7
- Herrick MK, DeBruyne K, Horoupian DS, Skare J, Vanefsky MA, Ong T. Massive leptomeningeal amyloidosis associated with a Val30Met transthyretin gene. Neurology 1996;47:988–92
- Blevins G, Macaulay R, Harder S, Fladeland D, Yamashita T, Yazaki M, Hamidi Asl K, et al. Oculoleptomeningeal amyloidosis in a large kindred with a new transthyretin variant Tyr69His. Neurology 2003;60:1625–30
- Zeldenrust SR, Skinner M, Share J, Benson MD. A new transthyretin variant (His 69) associated with vitreous amyloid in an FAP family. Amyloid 1994;1:17–22
- Obici L, Cortese A, Lozza A, Lucchetti J, Gobbi M, Palladini G, Perlini S, et al. Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. Amyloid 2012;19:34–6
- Montagna G, Cazzulani B, Obici L, Uggetti C, Giorgetti S, Porcari R, Ruggiero R, et al. Benefit of doxycycline treatment on articular disability caused by dialysis related amyloidosis. Amyloid 2013;20:173--8
- Ward JE, Ren R, Toraldo G, Soohoo P, Guan J, O'Hara C, Jasuja R, et al. Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis. Blood 2011;118:6610–17
- Sipe JD, Benson MD, Buxbaum JN, Ikeda S, Merlini G, Saraiva MJ, Westermark P, et al. Amyloid fibril protein nomenclature: 2012 recommendations from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid 2012;19:167–70